Evidence map›Paper›PMID 37155156›Full record

ArticleJAMA neurology2023

A Call to Action to Address Sex Differences in Alzheimer Disease Clinical Trials.

Rachel F Buckley, Jessica Gong, Mark Woodward

Abstract read
In one paragraph

Article in JAMA neurology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed.

  1. A multiverse analysis of the logical memory test and plasma biomarkers of Alzheimer's disease.Cortex; a journal devoted to the study of the nervous system and behavior · 2026
    Article
  2. Article
  3. Review
  4. Article
  5. Sex differences in Alzheimer's disease plasma biomarker levels and clinical utility.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  6. Article
  7. Article
  8. Article
  9. Integrating gender medicine into modern healthcare: Progress and barriers.European journal of clinical investigation · 2025
    Review
  10. Twenty years of therapeutic development in tauopathy mouse models: a scoping review.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. The higher benefit of lecanemab in males compared to females in CLARITY AD is probably due to a real sex effect.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Rachel F BuckleyDepartment of Neurology, Massachusetts General Hospital/Harvard Medical School, Boston.
Jessica GongGeorge Institute for Global Health, University of New South Wales, Sydney, Australia.
Mark WoodwardGeorge Institute for Global Health, University of New South Wales, Sydney, Australia.

Funding

Sex differences in the progression of Alzheimer's disease: is menopause the key?R00AG061238 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI BUCKLEY, RACHEL FRANCES · 2021 to 2023
$747k
NIA NIH HHS R00 AG061238
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Alzheimer DiseaseSex CharacteristicsFemaleHumansMale

Identifiers

PMID37155156
PMCPMC11446568

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.